Abstract 1106P
Background
Liver mets have been associated with poor response and survival in pts with MM treated with PD1 alone or in combination with anti-CTLA-4 (ipilimumab; PD1+IPI). Whether these pts benefit from PD1+IPI over PD1 is unknown. In MM pts with liver metastases, we sought to: a) determine objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) to PD1 vs PD1+IPI, and b) identify clinical predictors of response and survival to PD1+/-IPI.
Methods
MM pts with liver mets treated with 1st line PD1 or PD1+IPI were included. Demographics, patient and disease characteristics, baseline blood parameters and clinical outcomes were examined. Univariate and multivariate (MVA) analyses were performed to identify clinical predictors of response and survival.
Results
Of 533 MM pts treated with 1st line PD1 or PD1+IPI; 284 (53%) had PD1 and 249 (47%) had PD1+IPI. PD1 group had more ECOG PS ≥1 (53% vs 34%), but less BRAF V600 mutation (15% vs 33%) and stage M1D (15% vs 31%). Median follow-up from commencement of PD1+/-IPI was 47 months (42–51); ORR was 41%, higher in PD1+IPI (47%) vs PD1 (35%) (p=0.0027). PFS and OS at 1 year were 68% and 40%, respectively; non statistically higher with PD1+IPI (69%/43%) vs PD1 (67%/38%) (p>0.05). However, on MVA with multiple imputation for missing values and adjusting for predefined variables including age, gender, melanoma subtype (cutaneous non-acral, acral and mucosal), mutation status, ECOG PS, LDH and M1 substage (M1c versus M1d), PD1+IPI was associated with higher ORR (OR 2.21, 1.46 – 3.36; p<0.001), PFS (HR 0.73, 0.57 – 0.92; p=0.009) and OS (HR 0.71, 0.54 – 0.94; p=0.018) compared to PD1. Age (ORR, PFS), ECOG PS (OS), LDH (PFS, OS), M1 substage (ORR, PFS, OS), mutation status (PFS), melanoma subtype (OS) were also independent predictors of response and/or survival. Most pts ceased treatment due to progression (262 [53%]), and more pts stopped treatment due to toxicity in the PD1+IPI (n=77, 31%) vs PD1 (n=36, 14%) group.
Conclusions
In pts with liver metastases, 1st line PD1+IPI showed higher ORR and improved survival compared with PD1 alone. These data will help guide treatment selection for pts with melanoma liver metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
I. Pires da Silva: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche; Financial Interests, Personal, Other, Travel Support: BMS, Roche. S. Ugurel-Becker: Financial Interests, Personal, Research Funding: Bristol Myers Squibb, Merck Serono; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Novartis; Financial Interests, Personal, Other, meeting and travel support: Almirall, Bristol Myers Squibb, IGEA Clinical Biophysics, Merck Sharp & Dohme, Novartis, Pierre Fabre, Sun Pharma. M. Carlino: Financial Interests, Personal, Advisory Board: Amgen, BMS, Eisai, IDEAYA, MSD, Nektar, Novartis, OncoSec, Pierre Fabre, QBiotics, Regeneron, Roche, Merck, Sanofi; Financial Interests, Personal, Invited Speaker: BMS, MSD, Novartis. A.M. Menzies: Financial Interests, Personal, Advisory Board, advisory board: BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. M. Weichenthal: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck Sharp & Dohme, Roche, Novartis, Bristol Myers Squibb, Sanofi; Financial Interests, Personal, Advisory Role: Sun Pharma, Pierre Fabre; Financial Interests, Institutional, Research Funding: Merck Sharp & Dohme, Millennium, Bristol Myers Squibb, Johnson & Johnson, Novartis. P. Mohr: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Novartis, Amgen, Pierre Fabre, Merck, Sanofi; Financial Interests, Institutional, Research Funding: Merck Sharp & Dohme, Bristol Myers Squibb, Novartis; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Amgen, Roche, Sun Pharma, Sanofi. R. Gutzmer: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Novartis, Merck Serono, Almirall Hermal GmbH, Amgen, Sun Pharma, Pierre Fabre, Sanofi, Immunocore, 4SC; Financial Interests, Institutional, Research Funding: Pfizer, Novartis, Johnson & Johnson, Amgen, Merck Serono, Sun Pharma, Sanofi; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche, Merck Serono, Pierre Fabre, Sun Pharma. A.M. Arance Fernandez: Financial Interests, Personal, Advisory Board, Consultant /Advisory/Speaker/Travel, Accommodation, Expenses/: Pierre Fabre, Novartis, Roche, BMS, MSD, Merck, Sanofi; Financial Interests, Institutional, Other, Research Funding: Pierre Fabre, Novartis, MSD, BMS, Merck, Roche, Sanofi, Amgen. D. Johnson: Financial Interests, Personal, Advisory Board: BMS, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, OncoSec, Pfizer, Targovax, Teiko; Financial Interests, Personal, Funding: BMS, Incyte. P. Lorigan: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Pierre Fabre, BMS, MSD, Melagenix GmbH, Ultimovacs, MLA Diagnostics; Financial Interests, Personal, Research Funding: BMS, Pierre Fabre. D. Schadendorf: Financial Interests, Personal, Invited Speaker: BMS, Novartis, MSD, Roche, Merck Serono, Sanofi; Financial Interests, Personal, Advisory Board: BMS, Novartis, MSD, Immunocore, Pierre Fabre, Sanofi/Regeneron, Pfizer, Philogen, Neracare; Financial Interests, Personal, Steering Committee Member: Novartis, BMS, MSD; Financial Interests, Institutional, Coordinating PI: Novartis, BMS, MSD, Pierre Fabre; Financial Interests, Institutional, Research Grant: BMS, MSD; Financial Interests, Institutional, Local PI: Sanofi, Philogen; Non-Financial Interests, Member of Board of Directors: EORTC-MG. G.V. Long: Financial Interests, Personal, Speaker, Consultant, Advisor: Agenus, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Evaxion Biotech, Hexal AG, Highlight Therapeutics, Innovent Biologics, MSD, Novartis Pharma, OncoSec, PHMR, Pierre Fabre, Provectus, QBiotics, Regeneron. All other authors have declared no conflicts of interest.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13